Kornimate/medical-research-clean huggingface dataset:
pedal pump and leg lymphedema

Conditions: Lymphedema

Summary: chronic lymphedema in the lower extremities is a common problem found in older adults that can result in cellulitis, poor wound healing, venous stasis ulcers, and other comorbidities. compressive therapies are the present gold standard for the manual treatment of lymphedema in the lower extremities. however, the benefits of these compressive therapies are modest, and they are not well tolerated by older adults. an alternative manual treatment is the osteopathic pedal pump, an osteopathic manipulative treatment, that uses a rhythmical pumping motion instead of compressive force to move interstitial fluid from the lower extremities back to the circulatory system. however, the evidence that the osteopathic pedal pump can reduce volume in the lower extremities remains anecdotal. the aim of this study is to determine if the osteopathic pedal pump can reduce volume in the lower extremities among older adults with chronic lymphedema. leg volume will be measured using water displacement. older adults with chronic lymphedema of the lower extremities will be randomly assigned to one of two groups: a treatment group that will receive one session of the osteopathic pedal pump and a control group that will receive one session of a light touch treatment.


Eligibility criteria:
inclusion criteria: * age 55 years old or older * have lower leg lymphedema exclusion criteria: * any type of acute medical issue or exacerbation * a chronic medical condition (e.g., asthma, chronic obstructive pulmonary disease, congestive heart failure) * an active tissue infection or an open wound in the lower limb * an active bone fracture * acute deep venous thrombosis not fully anticoagulated * dementia
safety and efficacy of autologous transplantation of ipsc-rpe in the treatment of macular degeneration

Conditions: Macular Degeneration

Summary: this project intends to perform autologous transplantation of induced pluripotent stem cell-derived retinal pigment epithelium (ipsc-rpe). the clinical-grade rpe will be transplanted into subretinal space to treat refractory age-related macular degeneration. the efficacy and safety of rpe transplants to treat macular degeneration will be monitored and analyzed with results from edtrs, bcva, oct, erg, microperimetry, and fluorescein angiography, before and after the treatment.

the investigators will generate ipsc lines from recruited participants and differentiate the ipsc into rpe. autologous ipsc-derived rpe will be transplanted into participants eyes by subretinal injections. the safety and efficacy will be closely monitored and analyzed.

Eligibility criteria:
inclusion criteria: * aged 50-75 years; * clinical diagnosis is consistent with the definition of late dry amd in the age-related eye disease study (areds), with one or more \>250 um geographic atrophy in the fovea; * clinical diagnosis is wet amd, but no obvious efficacy after conventional treatment; * the bcva of the target eye will be 0.05 to 0.3; * voluntary as test subjects, informed consent, regular follow-up on time. exclusion criteria: * one-eyed subjects; * macular atrophy caused by other diseases in addition to amd; * suffer from retinitis pigmentosa, choroidal retinitis, central serous choroiditis, diabetic retinopathy, or other retinal vascular and degenerative diseases besides amd; * lens opacities (affecting the central vision), glaucoma, uveitis, retinal detachment, optic neuropathy, and other ocular histories; * other intraocular surgery histories besides cataract surgery; * combined with severe systemic diseases, such as heart failure, liver disease, renal insufficiency, cor pulmonale, copd in the previous 12 months; * combined with severe infectious diseases, such as hiv, hbv, hcv, syphilis, tuberculosis, etc; * abnormal blood coagulation function or other laboratory tests; * if female and of childbearing potential, pregnant, breastfeeding, or planning to become pregnant through the study; * if male, refuse to use barrier and spermicide contraception during the study; * malignant tumor and history of malignancy; * any immune deficiency; * allergy to tacrolimus or other macrolides; * any immune deficiency; * use glucocorticoids, immunosuppressive drugs, or antipsychotic drugs in the previous 3 months; * use anticoagulant, or the platelet function is still not restored to normal after stopping antiplatelet drugs for 10 days; * a history of addiction to alcoholism or prohibited drugs; * be participating in other intervention clinical trials or receiving other study medications; * poor compliance, difficulty to complete the study, or refusal to informed consent; * some other situations which might increase the risks of the subjects or interfere with clinical trials, such as mental disorders, cognitive dysfunction, etc.

Keywords: retinal disease macular degeneration stem cells rpe safety efficacy
strengthening the spleen and reducing phlegm method in improving radical resection rate of colorectal cancer

Conditions: Colorectal Cancer

Summary: this study will take disease-free survival time and recurrence and metastasis rate as the main evaluation indexes, to evaluate the clinical efficacy of strengthening the spleen and reducing phlegm method in patients with stage ii high-risk and stage iii colorectal cancer

the study enrolled 350 patients with stage ii high-risk and stage iii colorectal cancer who underwent adjuvant chemotherapy (based on a 5-fluorouracil（5-fu） regimen for at least 3 months) and patients who received chemotherapy for less than 3 months. the study will use a large sample, multicenter, randomized, double-blind study. the experimental group was given oral jianpi huatan dispensing granule, once a day in the morning and evening, 1 course per 1 month, a total of 3 courses; the control group of oral chinese medicine formula low dose control granules (including the test group dose 1 /10), 1 time each morning and evening, 1 course per month, for a total of 3 courses. the patients were followed up once a month during the treatment period and once every 3-6 months after the end of treatment until the patient relapsed, died or the study was over.some patients in the study will be tested for circulating tumor cells. main outcome measures is disease-free survival time（dfs）and metastasis recurrence rate in 1 year；secondary outcome measures：quality of life score: applied quality of life scale.metastasis recurrence rate in 2、3years.

Eligibility criteria:
inclusion criteria: 1. patients with colorectal cancer with clear pathological diagnosis and western medicine diagnostic criteria； 2. radical resection of colorectal cancer was performed and adjuvant chemotherapy (based on 5-fu regimens for at least 3 months) was completed within 3 months of the end of chemotherapy； 3. tumor node metastasis(tnm) stage is high-risk ii stage and iii stage； 4. age 18-80 years, sex unlimited； 5. no recurrence or metastasis by imaging or doctor's clinical judgement； 6. signed informed consent； note \* according to national comprehensive cancer network(nccn )clinical guidelines: phase ii:t3-4n0m0; high-risk phase ii is defined as follows:：a.t4;b. less than 12 lymph nodes were detected；c. preoperative intestinal obstruction, perforation of tumor site；d. poor histological differentiation (except highly unstable microsatellite)；e. neurological invasion and vascular tumor thrombus； f. positive or unknown margin, and insufficient margin safety distance. phase iii：t1-4n1-2m0. exclusion criteria: 1. history of previous or combined malignancies except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix； 2. combined with severe heart, liver and kidney disease； 3. any unstable condition or condition that may endanger patient safety and compliance with research, such as pregnancy, depression, manic-depressive disorder, obsessive-compulsive disorder, or schizophrenia; 4. the researchers determine that they were not suitable for the study.

Keywords: colorectal cancer traditional chinese medicine
whole-body vibration as a treatment for parkinson's disease

Conditions: Idiopathic Parkinson's Disease; Primary Parkinsonism

Summary: this study will evaluate whether whole-body vibration applied over a 12-week period is effective in treating motor symptoms of parkinson's disease.

parkinson's disease (pd) is a progressive neurodegenerative disease resulting in the loss of dopaminergic neurons projecting from the substantia nigra pars compacta to the striatum. whole-body vibration (wbv) is potentially beneficial in treating parkinson's disease because it has been shown to elicit effects specific to both the brain and muscular system. animal models of pd indicate that whole-body vibration can increase striatal dopamine levels, as well as the number of dopaminergic neurons in the substantia nigra. these findings were correlated with increased levels of brain-derived neurotrophic factor. in addition to the potentially neuroplastic effects, \>20 hz wbv has been shown to improve muscular performance. improved muscular performance is believed to be attributed to wbv induced neuromuscular effects rather than muscle hypertrophy, with the specific mechanism defined as the tonic vibration reflex.

Eligibility criteria:
inclusion criteria: * diagnosed with idiopathic parkinson's disease by a neurologist * currently taking anti-parkinsonian medication * able to stand for 2 minutes without assistance * able to walk 10 meters without assistance * ability to understand english instructions * normal or corrected vision exclusion criteria: * a neurological disease other than pd * recent stroke * cardiovascular disease * previous major hemorrhage * artificial pacemaker * currently pregnant * current participation in any physical therapy or experimental treatments * peripheral neuropathy, severe osteoporosis * visual impairments that cannot be corrected * clinically diagnosed with dementia * greater than mild dementia (screened using montreal cognitive assessment (moca) \<24 being excluded)

Keywords: parkinson's disease whole-body vibration wbv
foot posture index, hallux limitus in patients with chronic low back pain. gait with optogait sensor

Conditions: Hallux Limitus; Movement, Abnormal; Back Pain Lower Back Chronic

Summary: foot disorders have been recognized as being linked to chronic low back pain

foot disorders have been recognized as being linked to chronic low back pain (clbp), to improve knowledge of the relationship between the limitation of the movement range of hallux (hroml) is important about it can affect the back biomechanical . the aim of this research is to investigate if the hroml may appear as a risk factor of clbp hroml affect the foot position, and consecuently may induce to alter as compensatory mechanism the normal biomechanical of the leg, hip and back.

Eligibility criteria:
inclusion criteria: males and females between 18 to 65 years old hallux limitus in one or two feet - exclusion criteria: serious illness, current participation in another research study pregnancy previus foot or back surgery -

Keywords: foot hallux limitus back
a clinical trial on whole-brain radiotherapy with temozolomide concurrent chemotherapy or avoidance of hippocampus for patients of brain metastases

Conditions: Brain Metastasis; Radiation Therapy Complication

Summary: the purpose of this study is to evaluate the effects on neurocognitive function of whole-brain radiotherapy (wbrt) with/without tmz concurrent chemotherapy or avoidance of hippocampus for patients of brain metastases, as well as the feasibility and risk of avoidance of hippocampus during whole-brain radiotherapy.

this is a phase ii randomized clinical trial. it is reported that avoidance of hippocampus during whole-brain radiotherapy (wbrt) had benefits in preservation of memory for patients, and the use of concurrent tmz in radiotherapy for patients with brain metastases benefited for treating outcome. the purpose of this study is to evaluate the effects on neurocognitive function of whole-brain radiotherapy with/without tmz concurrent chemotherapy or avoidance of hippocampus for patients of brain metastases, as well as the feasibility and risk of avoidance of hippocampus during whole-brain radiotherapy.

Eligibility criteria:
inclusion criteria: * primary lesions diagnosed by pathology or cytology * brain metastases confirmed by brain mri or ct(\>3 brain metastases） * brain metastases beyond 5mm of hippocampus * male or female patients with age between 18 and 75 years old * karnofsky performance scores ≥ 60 * expected survival ≥ 6 months * no previous brain surgery or brain radiotherapy * without dysfunction of heart, lung, liver, kidney and hematopoiesis * the primary carcinoma is under control exclusion criteria: * mmse score \<27 * dysfunction of heart, lung, liver, kidney or hematopoiesis * severe neurological, mental or endocrine diseases * history of alcohol or drug abuse within 3 months * visual or hearing dysfunction, low education level, or other reasons leading to not capable of taking the mmse test * currently under treatment may effect patients' neurocognitive functions * patients participated in clinical trials of other drugs within last 3 months * other unsuitable reason

Keywords: brain metastasis whole-brain radiotherapy tmz avoidance of hippocampus
a prehabilitation program to boost postoperative functional capacity in surgical lung cancer patients

Conditions: Lung Cancer

Summary: this research study is evaluating a prehabiliation intervention designed to improve postoperative functional capacity (measured by 6-minure walking distance) in individuals undergoing lung resection for cancer.


Eligibility criteria:
inclusion criteria: 1. patients who are diagnosed of stage i, ii, or iiia non-small-cell lung carcinoma (nsclc) diagnosis, with or without pre-operative histologic confirmation 2. patients scheduled to undergo lung resection surgery at least two weeks from recruitment 3. patients with a eastern cooperative oncology group (ecog) score of 0 or 1 at recruitment 4. patients with no evidence of recurrent or progressive disease 5. patients aged 45-80 years 6. patients able to communicate in cantonese, mandarin, or english 7. patients is absence of any cognitive impairment 8. patients with a score of 6 minutes walking test (6mwt) ≤ 500 meters at baseline. \[rationale: a threshold value of 500 meters preoperative 6mwt predicts a higher risk of postoperative complications and prolonged los after lung resection\] 9. engagement in less than 150 minutes of moderate aerobic activity per week in the past 3 months exclusion criteria: 1. patients who had engaged in at least 150 minutes of moderate aerobic activity or 75 minutes of vigorous aerobic activity per week in the past three months 2. presence of another concurrent, actively treated malignancy 3. presence of chronic obstructive pulmonary disease 4. presence of significant comorbidities that impede ability to engage in exercise, such as congestive heart failure, orthopedic disorders of the lower limbs, respiratory failure, or the need for portable oxygen therapy for activities of daily living 5. not having a smart device to receive whatsapp messages

Keywords: prehabilitation physical activity lung resection functional capacity
use of thermal imaging camera to assess perfusion before and after vascular intervention

Conditions: Peripheral Arterial Disease; Critical Limb Ischemia; Critical Lower Limb Ischemia

Summary: this is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure. the main question this study aims to answer is: - are temperature measurements from a forward looking infrared (flir) camera of the lower extremity useful in predicting outcome of revascularization procedures?

this is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure. patients with lower extremity pad will be seen in office pre-intervention. consent to participate in the tic study will be acquired at this point. patients will be given a physical copy of their consent form at the time consent is obtained. during this initial visit or subsequent pre-procedural office visit, the smartphone-based thermal camera will be utilized to measure the temperature of the lower extremity foot, ankle, and leg at the plantar, dorsal, and lateral distributions. comorbidities and demographic factors will be documented from medical records at this time as well. data will be gathered at a consistent location to minimize impact of room temperature on measurements. patients will then undergo scheduled revascularization with the interventionist. post-intervention pictures will be taken immediately after revascularization. patients will then be seen again by the research team for follow-up thermal camera imaging, 1 week post-intervention, and weekly post intervention for at least 1 month but up to 6 months. thermal measurements will be correlated with intra-op imaging and clinical outcomes in data analysis.

Eligibility criteria:
inclusion criteria: * lower extremity peripheral artery disease with tissue loss consistent with rutherford classification v or vi. * planned lower extremity endovascular intervention exclusion criteria: * non-arterial ulcers * pregnant
interstim prospective database

Conditions: Urinary Retention; Urinary Incontinence; Pelvic Pain

Summary: the study is to collect information from patient charts and patient questionnaires to evaluate the effects of nerve stimulation therapy on urinary dysfunction.

men and women with urinary incontinence (leakage of urine), frequency, and bladder pain experience embarrassment, inconvenience, and a significant negative impact on their quality of life. although traditional treatments such as medications, diet modification, and bladder training provide relief for some people, others do not experience improvement with these treatments. recently, mechanical devices much like a heart pacemaker have been developed to stimulate the nerves (sacral and pudendal) responsible for controlling bladder function. during a two stage operation, a permanent electrical wire is implanted in the lower back and connected to a mechanical box (stimulator) implanted under the patients skin in the hip area. participants will be asked to complete a set of questionnaires (intake form, urinary incontinence treatment network (uitn) sexual activity questionnaire, interstitial cystitis symptom index and problem index, voiding diary) within 60 days prior to the procedure. preoperative clinical information such as primary diagnosis, history of failed therapies, and medical history will be collected from the physician office record, and operative information will be collected from the inpatient hospital record. after the two stage operation (3, 6, and 12 months, then yearly thereafter as long as the device is in place) participants will be sent questionnaires. upon completion and return to the study site

Eligibility criteria:
inclusion criteria: * all patients at least 18 years of age scheduled for sacral nerve stimulator implantation at william beaumont hospital, royal oak, michigan who give informed consent to participate in the project. exclusion criteria: * none

Keywords: urinary retention urinary incontinence pelvic pain
effect of dexamethasone on fetal heart rate variables in case of imminent preterm labor

Conditions: Fetal Heart Rate or Rhythm Abnormality Affecting Fetus

Summary: effect of dexamethasone on fetal heart rate variability in case of preterm labour: prospective cohort study

prospective cohort study on effect of dexamethasone on fetal heart rate variability in case of preterm labour

Eligibility criteria:
inclusion criteria: * preterm labor exclusion criteria: * twins
tight caloric balance in geriatric patients

Conditions: Nutrition Assessment

Summary: the aim of this study to assess the impact of nutritional support guided by repeated measurements of ree in geriatric patients following surgery for hip fractures. our hypothesis is that tight caloric control will reduce the risk of significant postoperative complications in geriatric patients following surgery for hip fractures. study design :prospective, single center, randomized, unblinded study. study population:geriatric patients following surgery for hip fractures.

the primary outcome: presence of postoperative complications,hospital length of stay. secondary outcomes: energy intake and calculated energy balance study procedure: eligible patients will be randomly assigned to 2 groups: the tight calorie (intervention)group and the control group.

Eligibility criteria:
inclusion criteria: patients older than 65 years who were admitted to the unit following hip fracture within 48 hours of the injury and in whom orthopedic surgery was considered the treatment of choice. exclusion criteria: patients were excluded if they presented to hospital \> 48 hours after the injury, were receiving steroids and/or immunosuppression therapy; in the presence of active oncologic disease, multiple fractures, diagnosed dementia or in the event that patients required supplemental nasal oxygen which precludes the measurement of resting energy expenditure.

Keywords: geriatric patients nutritional support
guidelines oriented approach to lipid lowering (goal) in canada

Conditions: Dyslipidemia

Summary: cross-sectional observational study designed to identify and describe the care gap in guideline-oriented low density lipoprotein cholesterol (ldl-c) management in canadian patients at high cardiovascular risk.

this is a cross-sectional observational study designed to provide real-life data on the current management of dyslipidemia in high cardiovascular risk patients in routine clinical practice. canadian guidelines recommend a target for ldl-c of ≤2.0 mmol/l (or ≥50% decrease) after treatment initiation in high-risk patients. the recommended first line treatment is statin therapy. available data clearly indicates that up to 50% of high risk patients do not achieve this important target because of statin inadequacy or intolerance leading to non-adherence. therefore this program aims to provide further insights into the challenges canadian physicians face in helping their high risk patients achieve guideline-recommended ldl-c.

Eligibility criteria:
inclusion criteria: 1. adults ≥ 18 years old 2. high risk for cardiovascular morbidity and mortality (at least one of the following): 1. clinical vascular disease: * coronary artery disease (cad): history of myocardial infarction (mi), coronary artery bypass grafting (cabg), percutaneous coronary intervention (pci), angiographic disease * cerebrovascular disease (cevd): history of cerebrovascular accident (cva) or transient ischemic attack (tia), carotid surgery * abdominal aortic aneurism (aaa): history of surgery/intervention * peripheral arterial disease (pad): history of surgery/intervention 2. familial hypercholesterolemia defined as ldl-c \> 5 mmol/l and one of: * typical physical findings (stigmata) such as tendon xanthomata, xanthelasma, and arcus corneae * personal history of early cardiovascular disease * family history of early cardiovascular disease or of marked hyperlipidemia 3. receiving current optimal (maximal or maximal tolerated) statin therapy for at least 3 months prior to patient enrolment 4. ldl-c \> 2.0 mmol/l measured within 6 months of patient enrolment date and while on (despite) maximal tolerated statin therapy (± other lipid modifying therapies). 5. desire and ability to execute the consent to participate. exclusion criteria: 1. current treatment with pcsk9 inhibitor 2. participation in an investigational study 3. prior participation in the goal program